EAM
AUPH icon

Eagle Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Eagle Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,210
Closed -$91.8K – 568
2023
Q4 		$91.8K Buy
+10,210
New +$84.1K ﹤0.01% 552

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eagle Asset Management's AUPH Position: Q1 2024 in Review

Eagle Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2024, closing a stake of 10,210 shares — an estimated $91.8K sold.

Eagle Asset Management first reported a position in AUPH in Q4 2023 and held it in 1 quarter. The position peaked at $91.8K in Q4 2023. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

  • Eagle Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Eagle Asset Management sold 10,210 Aurinia Pharmaceuticals shares in Q1 2024, an estimated $91.8K.
  • Eagle Asset Management first reported a position in Aurinia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Eagle Asset Management's Aurinia Pharmaceuticals position peaked at $91.8K in Q4 2023.
  • 179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on Eagle Asset Management's 13F filing for Q1 2024, filed 9 May 2024.